VIR Biotechnology

VIR Biotechnology is a biotech company that leverages the immune system to address critical unmet medical needs and improve patient outcomes. Its pipeline is built on two technology platforms: a next-generation antibody platform and the PRO-XTEN® protease-releasable masking technology, applied in infectious diseases and cancer respectively. Its foundational efforts are in infectious diseases, with a leading program in chronic hepatitis delta, complemented by strategic programs in oncology. The company has also developed antibody-based medicines for COVID-19 and Ebola. It was founded in San Francisco and has celebrated its 10-year anniversary.

VIR Biotechnology was founded in San Francisco. As it celebrated its 10-year anniversary, the company reflected on milestones from scientific breakthroughs and strategic partnerships to the people, values and experiences that make the company unique. Since its founding, it has built on its immunology expertise to achieve wins across infectious diseases and oncology, including the discovery of one of the first approved antibody treatments for Ebola virus and promising clinical data in one of the toughest-to-treat cancers.

Leveraging the immune system to address critical unmet medical needs in infectious diseases and oncology.

• 2020.07.10

  Reported2020.07.10

  Vir Biotechnology appoints Elliott Sigal to its board[6]Vir Biotechnology任命Elliott Sigal为董事会成员biospace.com

  Vir Biotechnology announced the appointment of Elliott Sigal to its board of directors.

• 2020.04.09

  Vir Biotechnology and Samsung Biologics agree on antibody manufacturing[7]Vir Biotechnology与Samsung Biologics达成抗体生产协议streetwisereports.com

  Vir Biotechnology and Samsung Biologics announced a manufacturing agreement valued at approximately US$362 million under which Samsung Biologics will provide large-scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody program. Production was scheduled to commence in October 2020; the parties were still negotiating complete details and hoped to execute a definitive agreement before July 31, 2020.

• 2020.02.25

  Reported2020.02.25

  WuXi Biologics and Vir Biotechnology partner on COVID-19 antibody development and production[8]药明生物与Vir Biotechnology合作开发和生产新冠抗体prnasia.com

  WuXi Biologics and Vir Biotechnology announced a collaboration agreement to develop and produce fully human monoclonal antibodies for treating COVID-19. WuXi Biologics will support cell-line, process and formulation development and early clinical production; the agreement provides WuXi Biologics commercialization rights in Greater China if the antibodies receive regulatory approval, while Vir holds rights in other global markets.

• 2019.10.10

  Reported2019.10.11

  Vir Biotechnology prices IPO at $20 per share[9]Vir Biotechnology将IPO定价为每股20美元cnbc.com

  Vir Biotechnology priced its initial public offering at $20 per share on Thursday and raised $142.9 million.

  Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.

Read more

1. 1Vir Biotechnology | Powering the Immune System to Transform Livesvir.bio
2. 2Our Board of Directors | Vir Biotechnologyvir.bio
3. 3Our Strategy | Vir Biotechnologyvir.bio
4. 410 Years of Vir Biotechnologyvir.bio
5. 5VIR Biotechnologywikidata.org
6. 6Vir Biotechnology任命Elliott Sigal为董事会成员biospace.com
7. 7Vir Biotechnology与Samsung Biologics达成抗体生产协议streetwisereports.com
8. 8药明生物与Vir Biotechnology合作开发和生产新冠抗体prnasia.com
9. 9Vir Biotechnology将IPO定价为每股20美元cnbc.com
10. 10药明生物与美国生物技术公司就新型冠状病毒抗体达成研发合作tech.sina.com.cn